A systematic review of sodium-glucose cotransporter 2 inhibitors and renal profiles among Japanese patients with type 2 diabetes mellitus

Table 1 Baseline characteristics in 13 randomized controlled trials

Study name	Concomitant medications	Doses [mg/day]	N^a	Dropout rate^b %	Duration weeks	Age year	HbA1c %	BMI kg/m²	eGFR mL/min/1.73 m²	Cardiac disease N
Wada 2022 [10]	ARB or ACEI	CANA 100 mg	154	18.5	108	62.5	7.8	26.9	55.7	Unclear
		Placebo	154
Kaku 2021 [13]	Sitagliptin	IPRA 50 mg	73	4.9	24	61.0	8.1	25.7	82.0	Unclear
		Placebo	70			60.0	8.0	26.0	83.4
Seino 2018 [14]	Insulin	LUSEO 2.5 mg	159	5.6	16	57.4	8.7	25.4	86.5	Unclear
		Placebo	74			57.1	8.8	25.2	87.9
Haneda 2016^c [15]	Unclear	LUSEO 2.5 mg	95	5.5	24	67.9	7.7	25.5	52.0	19
		Placebo	50			68.4	7.7	25.8	52.4	10
Kashiwagi 2015 A [16]	Antidiabetic agents	IPRA 50 mg	118	9.7	24	63.9	7.5	25.8	60.2	Unclear
		Placebo	46			65.7	7.6	25.0	62.7
Kashiwagi 2015B [17]	Sulfonylurea	IPRA 50 mg	165	12.8	24	59.6	8.4	25.8	84.2	Unclear
		Placebo	75			59.8	8.3	24.2	85.9
Kashiwagi 2015 C [18]	Pioglitazone	IPRA 50 mg	97	12.5	24	56.2	8.2	27.1	90.6	Unclear
		Placebo	54			56.1	8.4	27.1	91.6
Kashiwagi 2015D [19]	None	IPRA 50 mg	62	10.8	16	60.6	8.4	25.3	87.8	Unclear
		Placebo	67			58.3	8.3	25.6	86.1
Inagaki 2014 [20]	None	CANA 100 mg	90	11.4	24	58.4	8.0	25.6	81.4	Unclear
		CANA 200 mg	88			57.4	8.0	25.4	87.2
		Placebo	93			58.2	8.0	25.9	84.7
Kaku 2014 [21]	None	TOFO 10 mg	57	8.5	24	58.6	8.5	25.1	84.9	Unclear
		TOFO 20 mg	58			56.6	8.3	25.0	86.8
		TOFO 40 mg	58			57.0	8.4	25.8	86.0
		Placebo	56			56.8	8.4	26.0	83.8
Seino 2014 A [22]	None	LUSEO 1 mg	55	2.8	12	58.5	7.8	24.5	NR	Unclear
		LUSEO 2.5 mg	56			57.4	8.1	24.8	NR
		LUSEO 5 mg	54			57.3	7.9	26.4	NR
		LUSEO 10 mg	58			59.6	8.0	23.4	NR
		Placebo	57			57.1	7.9	25.2	NR
Seino 2014B [23]	None	LUSEO 0.5 mg	60	2.9	12	55.2	8.2	25.4	NR	Unclear
		LUSEO 2.5 mg	61			58.3	8.1	24.8	NR
		LUSEO 5 mg	61			56.8	8.2	24.5	NR
		Placebo	54			57.6	7.9	25.2	NR
Seino 2014 C [24]	None	LUSEO 2.5 mg	79	6.3	24	58.9	8.1	26.0	NR	Unclear
		Placebo	79			59.6	8.2	25.3	NR

CANA, canagliflozin; IPRA, ipragliflozin; LUSEO, luseogliflozin; TOFO, tofogliflozin; N, number of participants; BMI, body mass index; eGFR, estimated glomerular filtration rate, NR, not reported. ARB, angiotensin II receptor blocker; ACEI, angiotensin-converting enzyme inhibitor, ^aNumber of participants included in a full analysis set, ^bDropout rate during the double-blind period, ^cThe authors did not state a full-analysis set.

ISSN: 2055-0294